[1] |
Chen P, Li Z, Hu Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review[J].BMC Public Health, 2016, 16 (1): 1039.
|
[2] |
Leslie WD, Morin SN. Osteoporosis epidemiology 2013: implications for diagnosis, risk assessment, and treatment[J]. Curr Opin Rheumatol, 2014, 26 (4): 440-446.
|
[3] |
van der Velde RY, Wyers CE, Teesselink E, et al. Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity[J]. Bone, 2017, 94: 50-55.
|
[4] |
Chen Y, Wan JX, Jiang DW, et al. Efficacy of calcitriol in treating glucocorticoidinduced osteoporosis in patients with nephrotic syndrome: an open-label, randomized controlled study[J]. Clin Nephrol, 2015, 84 (5): 262-269.
|
[5] |
Giner M, Rios MJ, Montoya MJ, et al. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis[J]. Eur J Pharmacol, 2011, 650 (2-3): 682-687.
|
[6] |
Caniggia A, Nuti R, Lore F, et al. Long-term treatment with calcitriol in postmenopausal osteoporosis[J]. Metabolism, 1990, 39 (4 Suppl 1): 43-49.
|
[7] |
Enjuanes A, Ruiz-Gaspa S, Peris P, et al. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts[J]. Endocrine, 2010, 37 (1): 180-186.
|
[8] |
Giner M, Montoya MJ, Vazquez MA, et al. Modifying RANKL/OPG mRNA expression in differentiating and growing human primary osteoblasts[J].Horm Metab Res, 2008, 40 (12): 869-874.
|
[9] |
杨承镔,刘忠华,于仁波,等.女性绝经后骨质疏松症阿仑膦酸钠联合骨化三醇治疗的疗效[J].中国骨质疏松杂志, 2015, 21(1): 75-79.
|
[10] |
Zhang ZL, Liao EY, Xia WB, et al. Alendronate sodium/vitamin D(3) combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension[J].Osteoporos Int, 2015, 26 (9): 2365-2374.
|
[11] |
丁国强,汪艳燕,江华.老年人骨质疏松性髋部骨折术后应用阿伦膦酸钠联合骨化三醇胶丸的疗效[J].中国老年学杂志, 2014, 34(17): 4728-4730.
|
[12] |
Aydoğan NH,Özelİ,İltar S, et al. The effect of vitamin D and bisphosphonate on fracture healing: An experimental study[J]. J Clin Orthop Trauma, 2016, 7 (2): 90-94.
|
[13] |
Giuliani N, Pedrazzoni M, Passeri G, et al. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells[J]. Scand J Rheumatol, 1998, 27 (1): 38-41.
|
[14] |
Koch FP, Yekta SS, Merkel C, et al. The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro[J]. Head Face Med, 2010, 6: 12.
|
[15] |
Ebert R, Zeck S, Krug R, et al. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation[J]. Bone, 2009, 44 (5): 858-864.
|
[16] |
Panzavolta S, Torricelli P, Bracci B, et al. Alendronate and pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells[J].J Inorg Biochem, 2009, 103 (1): 101-106.
|
[17] |
董伟,戚孟春,邓久鹏,等.阿仑膦酸盐对成骨细胞相关基因RANKL、OPG表达的影响[J].南方医科大学学报, 2012, 32 (12): 1695-1698.
|
[18] |
Palmer L, Gidley J, Clare M, et al. Calcitriol and epidermal growth factor synergistically induce human osteoblast differentiation[J]. Mol Cell Endocrinol, 2006, 222(1-2): 9-17.
|
[19] |
唐晓琳,盂焕新,张立.骨化三醇对人牙周膜细胞维生素D受体、RANKL和骨保护因子表达的调节[J].中华口腔医学杂志, 2008, 43(12): 732-736.
|
[20] |
Piri F, Khosravi A, Moayeri A, et al. The effects of dietary supplements of calcium, Vitamin D and estrogen hormone on serum levels of OPG and RANKL cytokines and their relationship with increased bone density in rats[J].J Clin Diagn Res, 2016, 10 (9): Af01-AF04.
|